GHRP-6

Bowers et al. (Endocrine Reviews): Comprehensive characterization of GHRP-6 showing dose-dependent GH release in humans with peak response at 1-2mcg/kg IV. Established GHRP-6 as the prototype GH secretagogue.

Combined GHRP-6 + GHRH produces synergistic GH release 3-5x greater than either peptide alone, demonstrating distinct receptor mechanisms.

Berlanga et al.: GHRP-6 demonstrates significant cardioprotective effects in myocardial ischemia-reperfusion injury models, reducing infarct size and oxidative damage independent of GH release.

Study confirms GHRP-6 activates ghrelin receptors in the GI tract, increasing gastric emptying rate and appetite. Clinically relevant for cachexia/wasting conditions.

A 2026 preclinical study demonstrated that GHRP-6 attenuated myocardial tissue demise, reduced scarring, and improved left ventricle physiology in a rat model of myocardial infarction. Researchers found these effects may be mediated by upregulating pathways involved in antioxidant defenses and mitochondrial metabolic reprogramming.

A 2026 study demonstrated that GHRP-6 reduced neutrophilic alveolitis, improved alveolar-capillary permeability, and preserved lung parenchymal integrity in mice. Researchers found that the peptide limited collagen accumulation, suggesting potential pneumoprotective effects against acute lung injury and subsequent fibrosis.

A 2026 study found that orally administered salmon acylated ghrelin significantly increased food intake in common carp. The research demonstrated this orexigenic effect occurred locally via ghrelin receptors and sensory nerves rather than through systemic absorption.

A 2026 study demonstrated that intracerebroventricular injection of LEAP-2 significantly decreased food intake in broiler chickens. The research found that this hypophagic effect is mediated through interactions with ghrelin and cannabinoid receptors.

A 2025 study found that a self-assembling GHRP-6 peptide hydrogel enhanced the survival of renal tubular epithelial cells and reprogrammed their metabolism in a mouse model of acute kidney injury. The hydrogel demonstrated these effects by activating the mTOR-P70 pathway, offering insights into cellular protection.

A 2025 study demonstrated that aza-isotryptophan analogs of GHRP-6 exhibit promising CD36 receptor binding affinity and modulate inflammatory responses induced by the Toll-like receptor-2/6 heterodimer. Researchers also successfully characterized the peptide's beta-turn geometry using X-ray and NMR analyses.